Charles S. Berkman
Overview
Charles S. Berkman received an average of $3M in total compensation, including $471K in salary, at OmniAb from 2021 to 2023. Charles Berkman also received an average of $1M at Ligand Pharmaceuticals from 2007 to 2021.
- 2023
- 2022
- 2021
- 2020
- 2019
- 2018
- 2017
- 2016
- 2015
OmniAbChief Legal Officer and Secretary
OmniAbChief Legal Officer and Secretary
OmniAbChief Legal Officer and Secretary
Ligand PharmaceuticalsSenior Vice President and General Counsel
Ligand PharmaceuticalsSenior Vice President and General Counsel
Ligand PharmaceuticalsSenior Vice President and General Counsel
Ligand PharmaceuticalsSenior Vice President and General Counsel
Ligand PharmaceuticalsSenior Vice President and General Counsel
Ligand PharmaceuticalsVice President and General Counsel
Ligand PharmaceuticalsVice President and General Counsel
Source: SEC filings on April 26, 2024, May 1, 2023, April 22, 2022, November 12, 2020, April 24, 2020, April 30, 2018, April 14, 2017, April 12, 2016, March 12, 2015, April 21, 2014, April 25, 2013, and April 29, 2009.
Related executives
We found nine more executives who work or worked at OmniAb and Ligand Pharmaceuticals.
Matthew Foehr
OmniAb
Chief Executive Officer
Kurt Gustafson
OmniAb
Chief Financial Officer
John Higgins
Ligand Pharmaceuticals
Chief Executive Officer
Matthew Korenberg
Ligand Pharmaceuticals
Chief Financial Officer
Nishan de Silva
Ligand Pharmaceuticals
Chief Financial Officer
Melanie Herman
Ligand Pharmaceuticals
Chief Financial Officer
John Sharp
Ligand Pharmaceuticals
Chief Financial Officer
Martin Meglasson
Ligand Pharmaceuticals